916056-79-6

Basic information

• Product Name: ADX-102 (NS-2)
• Synonyms: ADX-102 (NS-2);Reproxalap
• CAS NO: 916056-79-6
• Molecular Formula: C12H13ClN2O
• Molecular Weight: 236.69742
• EINECS: -0
• Mol File: 916056-79-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ADX-102 (NS-2)(CAS DataBase Reference)
• NIST Chemistry Reference: ADX-102 (NS-2)(916056-79-6)
• EPA Substance Registry System: ADX-102 (NS-2)(916056-79-6)

Safety Data

• Hazardous Substances Data: 916056-79-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ADX-102 (NS-2) is used as an anti-inflammatory and analgesic agent for the treatment of inflammatory conditions such as osteoarthritis and tendinitis. It helps reduce pain and inflammation, offering a safe and effective alternative to traditional anti-inflammatory medications.
Used in Topical Gel Formulation:
ADX-102 (NS-2) is used as an active ingredient in topical gel formulations for localized application. This form of administration allows for targeted treatment of affected areas, minimizing systemic side effects and enhancing patient compliance. The development of a topical gel containing ADX-102 (NS-2) has the potential to revolutionize the management of inflammatory conditions, providing a convenient and effective treatment option.

Upstream product

• 1448228-06-5 1-(6-chloro-2-(ethoxycarbonyl)quinolin-3-yl)pyridin-1-ium bromide 
• 6628-86-0 5-chloro-2-nitrobenzaldehyde 
• 676-58-4 methylmagnesium chloride 
• 20028-53-9 2-amino-5-chlorobenzaldehyde 
• 41491-92-3 1-(3-ethoxy-2,3-dioxopropyl)pyridin-1-ium bromide 

Downstream Products

• 1615680-56-2 2-(6-chloro-((3-((E)-2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenylidene)amino)quinolin-2-yl)propan-2-ol 
• 1615680-58-4 C₃₂H₃₉ClN₂O 

Relevant articles and documents

ALDEHYDE CONJUGATES AND USES THEREOF

The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

PROCESS FOR PREPARATION OF ALDEHYDE SCAVENGER AND INTERMEDIATES

The present invention relates to methods for synthesizing compounds, and to intermediates thereto, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis.

ALDEHYDE TRAPPING COMPOUNDS AND METHODS OF USE THEREOF

The present invention provides compounds and methods for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

POLYMORPHIC COMPOUNDS AND USES THEREOF

The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions, in which aldehyde toxicity is implicated in the pathogenesis, by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.

DEUTERATED COMPOUNDS AND USES THEREOF

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

PROCESS TO PREPARE 6-CHLORO-3-AMINO-2-(2-HYDROXYPROPYL)-1-AZANAPHTHALENE

This invention relates to a process for the preparation of 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanapthalene. It comprises treating 6-chloro-3-pyridylium-2-ethoxycarbonyl-1-azanaphthanlene bromide with morpholine at about 80° C., followed by treating the product thereof with methylmagnesium chloride.